Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
This study reveals genotype-specific differences in atrial fibrillation (AF) risk among dilated cardiomyopathy (DCM) patients, highlighting LMNA mutations as a major predictor of incident AF and its association with worse clinical outcomes,
A novel left atrial (LA) staging system, integrating hemodynamic load and contractile function, predicts new-onset atrial fibrillation risk in hypertrophic cardiomyopathy and may guide tailored AF surveillance.
This study analyzes global trends comparing ischemic stroke burdens linked to diabetes and atrial fibrillation, revealing a rising impact of diabetes-related stroke and highlighting the need for targeted interventions.
This Finnish nationwide study demonstrates that patients with atrial flutter have a substantially lower risk of ischaemic stroke compared to those with atrial fibrillation, highlighting important differences in thromboembolic risk profiles
This study reveals distinct left atrial structural and functional changes associated with obesity in atrial fibrillation patients, highlighting a load-related atrial remodeling that may underlie increased risks of atrial fibrillation and he
This article explores the latest evidence on antithrombotic therapy after PCI in patients with atrial fibrillation, highlighting the balance between bleeding risk and prevention of ischemic events.
This prospective registry reveals a significantly increased risk of stroke or transient ischemic attack within 30 days after pulsed field ablation compared to radiofrequency ablation for atrial fibrillation, highlighting important safety co
Clonal hematopoiesis (CHIP) significantly associates with increased silent brain lesions and progressive cognitive decline in atrial fibrillation patients, highlighting a novel neurovascular risk factor with implications for patient managem
This nationwide Finnish cohort study reveals that gout increases ischemic stroke risk in atrial fibrillation patients, with urate-lowering therapy linked to reduced stroke incidence, underscoring gout’s potential role in stroke risk s
This review synthesizes evidence linking NOAC use to slower cognitive decline and improved clinical outcomes in patients with atrial fibrillation and Alzheimer’s disease, highlighting advantages over warfarin and non-use.
This study evaluates the real-world effectiveness and safety of direct oral anticoagulants versus warfarin in Asian patients with atrial fibrillation and mitral stenosis, revealing higher stroke yet lower myocardial infarction risk with DOA
The AZALEA-TIMI 71 study demonstrates that factor XI inhibition with abelacimab reduces bleeding risk in atrial fibrillation patients regardless of prior oral anticoagulation experience, with a potentially greater absolute benefit in antico
This study evaluates the incidence, severity, and predictors of extracranial bleeding in atrial fibrillation patients on oral anticoagulants, highlighting its substantial burden beyond major bleeds and informing bleeding risk management.
A machine learning model using electronic health records effectively identifies patients at high risk of atrial fibrillation, enabling targeted screening and early diagnosis to prevent stroke.
A predefined subanalysis of EAST-AFNET 4 shows early rhythm control safely reduces cardiovascular events in recently diagnosed AF patients with CKD, with a trend toward greater benefit in this high-risk group.
Recent decades saw increased anticoagulant use and reduced stroke risk in elderly AF patients, especially with DOACs, but bleeding risks rise notably in very elderly patients, highlighting tailored management needs.
This review synthesizes evidence that high adolescent cardiorespiratory fitness slightly elevates early adult atrial fibrillation risk but substantially reduces cardiovascular disease incidence later in life, with familial confounders accou
In frail elderly Asian AF patients stable on warfarin, transitioning to DOACs increased risks of bleeding, thromboembolic events, and mortality, emphasizing cautious individualized management.
This sham-controlled trial demonstrates that pulsed field ablation significantly reduces atrial fibrillation recurrence, burden, and improves quality of life and psychological distress compared to sham treatment.
Continuous monitoring in heart failure patients revealed a high burden of arrhythmias linked to more interventions, hospitalizations, and heart failure events, but not altered by the study’s congestion-management strategy.